BridgeBio Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	642.95	681.1	375.94	376.69	393.77	356.08
Short-Term Investments	2.99	-	58.95	95.23	442.89	251.01
Cash & Short-Term Investments	645.94	681.1	434.88	471.92	836.66	607.09
Cash Growth	142.54%	56.62%	-7.85%	-43.59%	37.81%	11.19%
Accounts Receivable	116.52	4.72	1.75	17.08	19.75	-
Receivables	116.52	4.72	1.75	17.08	19.75	-
Prepaid Expenses	47.37	31.04	24.31	21.92	32.27	35.59
Restricted Cash	0.13	0.13	16.65	37.93	0.18	0.14
Other Current Assets	4.9	3.7	-	-	-	-
Total Current Assets	839.38	720.69	477.59	548.85	888.86	642.82
Property, Plant & Equipment	12.38	12.78	19.84	25.25	45.97	36.83
Long-Term Investments	92.17	143.75	1.6	-	-	-
Other Intangible Assets	28.8	23.93	26.32	28.71	44.93	-
Other Long-Term Assets	25.52	18.2	21.03	20.22	33.03	23.93
Total Assets	998.25	919.34	546.38	623.04	1,013	703.59
Accounts Payable	18.7	9.62	10.66	11.56	11.88	8.95
Accrued Expenses	183.52	124.08	116.97	95.54	116.75	71.9
Current Portion of Long-Term Debt	-	-	-	-	-	1.46
Current Portion of Leases	5.29	4.51	4.13	3.68	4.94	3.8
Current Unearned Revenue	9.09	14.6	6.1	8.16	-	-
Other Current Liabilities	-	1.6	6	2.5	1.5	9.55
Total Current Liabilities	216.6	154.4	143.84	121.43	135.07	95.65
Long-Term Debt	1,851	1,721	1,727	1,708	1,704	475.86
Long-Term Leases	3.43	4.7	8.98	12.27	17.43	14.68
Long-Term Unearned Revenue	13.13	17.1	3.73	7.1	-	-
Long-Term Deferred Tax Liabilities	-	-	-	-	-	1.1
Other Long-Term Liabilities	836.81	479.38	5.63	19.54	22.07	8.42
Total Liabilities	2,921	2,377	1,889	1,868	1,878	595.7
Common Stock	0.2	0.2	0.18	0.16	0.15	0.13
Additional Paid-In Capital	2,018	1,903	1,481	938.7	841.53	1,021
Retained Earnings	-3,628	-3,096	-2,561	-1,918	-1,437	-888.76
Treasury Stock	-323.28	-275	-275	-275	-275	-75
Comprehensive Income & Other	0	0.01	0.03	-0.33	-0.13	0.19
Total Common Equity	-1,933	-1,468	-1,354	-1,255	-870.41	57.91
Minority Interest	10.34	10.29	11.72	9.69	4.84	49.98
Shareholders' Equity	-1,923	-1,458	-1,343	-1,245	-865.58	107.89
Total Liabilities & Equity	998.25	919.34	546.38	623.04	1,013	703.59
Total Debt	1,860	1,731	1,740	1,724	1,726	495.79
Net Cash (Debt)	-1,214	-1,049	-1,305	-1,252	-889.51	111.31
Net Cash Growth	-	-	-	-	-	-77.07%
Net Cash Per Share	-6.37	-5.64	-8.02	-8.49	-6.16	0.94
Filing Date Shares Outstanding	192.71	190.19	175.83	151.37	147.61	146.54
Total Common Shares Outstanding	192.63	190.04	175.08	150.63	147.34	122.85
Working Capital	622.78	566.29	333.75	427.43	753.79	547.18
Book Value Per Share	-10.03	-7.72	-7.73	-8.33	-5.91	0.47
Tangible Book Value	-1,962	-1,492	-1,381	-1,283	-915.35	57.91
Tangible Book Value Per Share	-10.18	-7.85	-7.89	-8.52	-6.21	0.47

Source: S&P Global Market Intelligence. Standard template. Financial Sources.